伊马替尼与骨和矿物质代谢改变 - Suppr

Suppr

超能文献

Imatinib and altered bone and mineral metabolism.

作者信息

Owen Samantha, Hatfield Alan, Letvak Laurie

出版信息

N Engl J Med. 2006 Aug 10;355(6):627; author reply 628-9. doi: 10.1056/NEJMc061565.

DOI:10.1056/NEJMc061565

PMID:16899786

Abstract

摘要

相似文献

Imatinib and altered bone and mineral metabolism.伊马替尼与骨和矿物质代谢改变

N Engl J Med. 2006 Aug 10;355(6):627; author reply 628-9. doi: 10.1056/NEJMc061565.

Imatinib and altered bone and mineral metabolism.伊马替尼与骨和矿物质代谢改变

N Engl J Med. 2006 Aug 10;355(6):628; author reply 628-9.

Imatinib and altered bone and mineral metabolism.伊马替尼与骨骼和矿物质代谢改变

N Engl J Med. 2006 Aug 10;355(6):627; author reply 628-9.

Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.伊马替尼治疗引起的部分范科尼综合征：尿磷丢失的新原因。

Am J Kidney Dis. 2008 Feb;51(2):298-301. doi: 10.1053/j.ajkd.2007.10.039.

Altered bone and mineral metabolism in patients receiving imatinib mesylate.接受甲磺酸伊马替尼治疗的患者骨与矿物质代谢改变

N Engl J Med. 2006 May 11;354(19):2006-13. doi: 10.1056/NEJMoa051140.

Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.

N Engl J Med. 2006 Dec 7;355(23):2494-5. doi: 10.1056/NEJMc062388.

Imatinib as a possible cause of severe rhabdomyolysis.伊马替尼可能是严重横纹肌溶解症的病因。

N Engl J Med. 2008 Jun 19;358(25):2746-7. doi: 10.1056/NEJMc0708896.

Another look at imatinib mesylate.再看甲磺酸伊马替尼。

N Engl J Med. 2007 Mar 15;356(11):1183; author reply 1183. doi: 10.1056/NEJMc063721.

Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?甲磺酸伊马替尼的心脏毒性：是极为罕见的现象还是主要副作用？

Ann Rheum Dis. 2007 Jun;66(6):836. doi: 10.1136/ard.2006.067710.

Dermatological toxicity of imatinib mesylate.甲磺酸伊马替尼的皮肤毒性

J Assoc Physicians India. 2005 Apr;53:298.

引用本文的文献

Non-Severe Hypophosphatemia in Older Patients: A Systematic Review.老年患者非重度低磷血症：一项系统评价

Nutrients. 2025 Apr 16;17(8):1354. doi: 10.3390/nu17081354.

Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies.抗癌治疗相关的急性肾损伤：小分子药物和靶向治疗。

Kidney360. 2024 Nov 1;5(11):1750-1762. doi: 10.34067/KID.0000000566. Epub 2024 Aug 26.

Hypophosphatemia in cancer patients.癌症患者的低磷血症

Clin Kidney J. 2021 Apr 15;14(11):2304-2315. doi: 10.1093/ckj/sfab078. eCollection 2021 Nov.

Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.酪氨酸激酶抑制剂通过抑制血小板衍生生长因子受体β（PDGFRβ）来调节骨保护素（OPG）。

PLoS One. 2016 Oct 13;11(10):e0164727. doi: 10.1371/journal.pone.0164727. eCollection 2016.

A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib.1例与伊布替尼相关的低磷血症伴尿磷排泄增加病例

Case Rep Oncol. 2016 Apr 16;9(1):223-7. doi: 10.1159/000445798. eCollection 2016 Jan-Apr.

Clinical review: kinase inhibitors: adverse effects related to the endocrine system.临床综述：激酶抑制剂：与内分泌系统相关的不良反应。

J Clin Endocrinol Metab. 2013 Apr;98(4):1333-42. doi: 10.1210/jc.2012-4085. Epub 2013 Feb 28.

Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia.数字图像分析作为一种评估伊马替尼对慢性髓性白血病患者小梁骨影响的工具。

Hum Pathol. 2012 Dec;43(12):2354-9. doi: 10.1016/j.humpath.2012.04.012. Epub 2012 Aug 29.

Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients.转移性肾细胞癌患者使用酪氨酸激酶抑制剂治疗与药物诱导的甲状旁腺功能亢进有关：59 例患者的单中心经验。

World J Urol. 2010 Jun;28(3):311-7. doi: 10.1007/s00345-010-0558-y. Epub 2010 May 5.

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).治疗慢性髓性白血病的选择：聚焦伊马替尼（格列卫，商品名）。

Ther Clin Risk Manag. 2008 Feb;4(1):163-87.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验